Spots Global Cancer Trial Database for Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination

Official Title: Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination

Study ID: NCT01613053

Conditions

Gastrointestinal Stromal Tumor

Interventions

Glivec

Study Description

Brief Summary: Continuation of drug supply in Chinese patients after CAMN107DBR01study termination.

Detailed Description: Five patients who are on treatment of imatinib and deriving clinical benefit after CAMN107DBR01 study termination and written informed consent obtained will enter the trial, all five patients will receive Glivec (8oomg per day) treatment until tumor progression \[by RECIST guidelines, version 1.0\], unacceptable toxicity, death or withdrawal of consent.